A Phase 1 Study of BLZ-100 Administered by Intravenous Injection in Subjects With Soft Tissue Sarcoma Undergoing Surgery

Trial Profile

A Phase 1 Study of BLZ-100 Administered by Intravenous Injection in Subjects With Soft Tissue Sarcoma Undergoing Surgery

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Tozuleristide (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors Blaze Bioscience
  • Most Recent Events

    • 24 May 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 24 May 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 18 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top